Amarantus Therapeutics, Inc.

NOKOMIS, Fla.--(BUSINESS WIRE)--Rainbow Coral Corp.’s (OTCBB: RBCC) pending joint venture partner Amarantus BioScience, Inc. (OTCBB: AMBS) announced last week that it has licensed a highly promising new diagnostic known as the LymPro Alzheimer's Disease Diagnostic Blood Test (LymPro) from Memory Dx, LLC (MDx). LymPro works by identifying immune-based biomarkers in the blood of patients suffering from Alzheimer’s, thereby diagnosing the disease and allowing physicians to definitively differentiate from other forms of dementia, reducing the need for much costlier brain scans. The diagnostic has the potential to become an invaluable new tool in Alzheimer's clinical trials, where there has been a well-documented history of patient recruitment errors related to inaccurate diagnosis of the disease.